Company / Free Cash Flow
Cardiff Oncology, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$38.0M
FY2025
5-year range
-$38.0M / -$16.5M
FY2021-FY2025
Trend
-20.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 10 years, ranging from -$38M in FY2025 to -$13M in FY2016.
Based on SEC 10-K filings.
-$38M in FY2025.
Declined from -$35M to -$38M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow decreased 20.6% year-over-year.
- Peak free cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$38.0M | -20.6% |
| FY2024 | -$31.5M | +9.6% |
| FY2023 | -$34.8M | -49.8% |
| FY2022 | -$23.2M | -40.7% |
| FY2021 | -$16.5M | +0.0% |
| FY2020 | -$16.5M | -23.9% |
| FY2019 | -$13.3M | +43.0% |
| FY2018 | -$23.4M | +26.6% |
| FY2017 | -$31.9M | -143.4% |
| FY2016 | -$13.1M | +46.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026